SNTI on Nasdaq
Senti Biosciences Holdings, Inc.
American biological products company based in South San Francisco.
Price unavailable
Last updated Oct 18, 2026.
Overview
Compare with Allogene Therapeutics, Inc., Opthea Ltd or Enzon Pharmaceuticals, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development100¢$37.6M
Out of $22.0K in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Collaboration revenue - related party | $22.0K | $0 |
| General and administrative | $26.2M | $26.4M |
| Impairment of long-lived assets | $5.1M | $313.0K |
| Total operating expenses | $68.8M | $61.0M |
| Loss from operations | -$68.8M | -$61.0M |
| Interest income | $927.0K | $948.0K |
| Other income, net | $800.0K | $200.0K |
| Change in fair value of Preferred Stock Tranche Liability - related party | $0 | $13.4M |
| Change in fair value of contingent earnout liability | $0 | $20.0K |
| Total other income, net | $7.3M | $8.2M |
| Net loss | -$61.4M | -$52.8M |
| Comprehensive loss | -$61.4M | -$52.8M |
| Net loss per share, basic (in dollars per share) | -$2.73 | -$12.03 |
| Net loss per share, diluted (in dollars per share) | -$2.73 | -$12.03 |
| Weighted-average shares outstanding, basic (in shares) | 22.5M shares | 4.6M shares |
| Weighted-average shares outstanding, diluted (in shares) | 22.5M shares | 4.6M shares |
| Research and development | $37.6M | $34.4M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.3
| Period ending | 2025-12-31 | 2024-12-31 | 2024-06-30 | 2023-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $16.4M | $48.3M | ||
| Total current assets | $23.3M | $59.0M | ||
| Restricted cash | $3.5M | $3.5M | ||
| Property and equipment, net | $12.9M | $21.3M | ||
| Operating lease right-of-use assets | $11.5M | $13.9M | ||
| Other non-current assets | $19.0K | $105.0K | ||
| TOTAL ASSETS | $51.2M | $97.8M | ||
| Accounts payable | $2.9M | $1.5M | ||
| Accrued expenses and other current liabilities | $5.4M | $6.4M | ||
| Operating lease liabilities, current | $5.3M | $4.6M | ||
| Deferred revenue, current - related party | $43.0K | $0 | ||
| GeneFab sublease deferred income - related party | $304.0K | $660.0K | ||
| Total current liabilities | $14.0M | $13.1M | ||
| Operating lease liabilities, non-current | $23.6M | $28.9M | ||
| Other non-current liabilities | $8.1M | $5.0M | ||
| TOTAL LIABILITIES | $45.6M | $47.1M | ||
| Series A redeemable convertible preferred stock, $0.0001 par value; zero and 21,200 shares authorized as of December 31, 2025 and 2024, respectively; zero and 21,157 shares issued and outstanding as of December 31, 2025 and 2024, respectively; aggregate liquidation preference of zero and $147,647 as of December 31, 2025 and 2024, respectively | $0 | $25.1M | $0 | |
| Common stock, $0.0001 par value; 500,000,000 shares authorized as of both December 31, 2025 and 2024; 30,879,355 and 4,829,035 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $3.0K | $1.0K | ||
| Additional paid-in capital | $364.2M | $322.8M | ||
| Accumulated deficit | -$358.6M | -$297.1M | ||
| TOTAL STOCKHOLDERS EQUITY | $5.6M | $25.6M | $66.9M | |
| TOTAL LIABILITIES AND STOCKHOLDERS EQUITY | $51.2M | $97.8M | ||
| Series A redeemable convertible preferred stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Series A redeemable convertible preferred stock, shares authorized (in shares) | 0 shares | 21.2K shares | ||
| Series A redeemable convertible preferred stock, shares issued (in shares) | 0 shares | 21.2K shares | ||
| Series A redeemable convertible preferred stock, shares outstanding (in shares) | 0 shares | 21.2K shares | 0 shares | |
| Series A redeemable convertible preferred stock, liquidation preference | $0 | $147.6M | ||
| Common stock, par or stated value (in dollars per share) | $0.00 | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 500.0M shares | 500.0M shares | ||
| Common stock, shares issued (in shares) | 30.9M shares | 4.8M shares | ||
| Common stock, shares outstanding (in shares) | 30.9M shares | 4.8M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2024-06-30 | 2023-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $16.4M | $48.3M | ||
| Total current assets | $23.3M | $59.0M | ||
| Restricted cash | $3.5M | $3.5M | ||
| Property and equipment, net | $12.9M | $21.3M | ||
| Operating lease right-of-use assets | $11.5M | $13.9M | ||
| Other non-current assets | $19.0K | $105.0K | ||
| TOTAL ASSETS | $51.2M | $97.8M | ||
| Accounts payable | $2.9M | $1.5M | ||
| Accrued expenses and other current liabilities | $5.4M | $6.4M | ||
| Operating lease liabilities, current | $5.3M | $4.6M | ||
| Deferred revenue, current - related party | $43.0K | $0 | ||
| GeneFab sublease deferred income - related party | $304.0K | $660.0K | ||
| Total current liabilities | $14.0M | $13.1M | ||
| Operating lease liabilities, non-current | $23.6M | $28.9M | ||
| Other non-current liabilities | $8.1M | $5.0M | ||
| TOTAL LIABILITIES | $45.6M | $47.1M | ||
| Series A redeemable convertible preferred stock, $0.0001 par value; zero and 21,200 shares authorized as of December 31, 2025 and 2024, respectively; zero and 21,157 shares issued and outstanding as of December 31, 2025 and 2024, respectively; aggregate liquidation preference of zero and $147,647 as of December 31, 2025 and 2024, respectively | $0 | $25.1M | $0 | |
| Common stock, $0.0001 par value; 500,000,000 shares authorized as of both December 31, 2025 and 2024; 30,879,355 and 4,829,035 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $3.0K | $1.0K | ||
| Additional paid-in capital | $364.2M | $322.8M | ||
| Accumulated deficit | -$358.6M | -$297.1M | ||
| TOTAL STOCKHOLDERS EQUITY | $5.6M | $25.6M | $66.9M | |
| TOTAL LIABILITIES AND STOCKHOLDERS EQUITY | $51.2M | $97.8M | ||
| Series A redeemable convertible preferred stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Series A redeemable convertible preferred stock, shares authorized (in shares) | 0 shares | 21.2K shares | ||
| Series A redeemable convertible preferred stock, shares issued (in shares) | 0 shares | 21.2K shares | ||
| Series A redeemable convertible preferred stock, shares outstanding (in shares) | 0 shares | 21.2K shares | 0 shares | |
| Series A redeemable convertible preferred stock, liquidation preference | $0 | $147.6M | ||
| Common stock, par or stated value (in dollars per share) | $0.00 | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 500.0M shares | 500.0M shares | ||
| Common stock, shares issued (in shares) | 30.9M shares | 4.8M shares | ||
| Common stock, shares outstanding (in shares) | 30.9M shares | 4.8M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$61.4M | -$52.8M |
| Stock-based compensation | $5.7M | $1.8M |
| Depreciation | $3.6M | $3.8M |
| Impairment of long-lived assets | $5.1M | $313.0K |
| Change in fair value of Preferred Stock Tranche liability - related party | $0 | -$13.4M |
| Change in fair value of contingent earnout liability | $0 | -$20.0K |
| Other non-cash charges | $39.0K | $115.0K |
| Operating lease right-of-use assets | $2.3M | $2.0M |
| Accounts payable | $1.7M | $797.0K |
| Accrued expenses and other current liabilities | $559.0K | -$671.0K |
| Operating lease liabilities | -$4.6M | -$4.0M |
| GeneFab sublease deferred income - related party | -$356.0K | -$329.0K |
| Deferred revenue, current - related party | $43.0K | $0 |
| Other non-current liabilities | $0 | $149.0K |
| Net cash used in operating activities | -$43.4M | -$41.4M |
| Purchases of property and equipment | -$196.0K | -$26.0K |
| Proceeds from sale of property and equipment | $12.0K | $60.0K |
| Net cash provided by (used in) investing activities | -$184.0K | $34.0K |
| Proceeds from CIRM Grant | $3.0M | $4.9M |
| Payment of issuance costs | -$2.5M | -$229.0K |
| Proceeds from private placement, net of fees paid to investor | $0 | $47.3M |
| Net cash provided by financing activities | $11.8M | $53.7M |
| NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH | -$31.9M | $12.4M |
| Unpaid Issuance Costs | $34.0K | $1.9M |
No quarter-by-quarter statement was filed.
Compare Senti Biosciences Holdings, Inc. with another company
Leadership
Who has led Senti Biosciences Holdings, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
Chief operating officer
2025
- Chief executive officerTimothy K. Lu Jun 15, 2022 to now9
- PresidentTimothy K. Lu Jun 15, 2022 to Feb 2, 20249
- Chief financial officerJohn Harry Cross Iii. Mar 11, 2025 to now10
- Chief financial officerYvonne Li May 9, 2024 to May 9, 202411
- Chief financial officerDeborah Knobelman Jun 15, 2022 to Feb 2, 202412
- Chief financial officerMark Afrasiabi May 25, 2021 to May 25, 202113
- Chief operating officerCurt A. Herberts Iii. Jun 15, 2022 to Jun 15, 202214
Board members and other officers (14)
- Chief Technology OfficerPhilip J. Lee Jun 15, 2022 to Feb 2, 202315
- Chief Medical & Devt. OfficerKanya Rajangam Jul 15, 2022 to now16
- Chief Business OfficerRowan E. Chapman May 25, 2021 to May 25, 202117
- Board memberFeng Hsiung Mar 11, 2025 to now18
- Board memberBryan Daniel Baum Jul 21, 2025 to now19
- Board memberFran Schulz Dec 10, 2024 to now20
- Board memberBrenda Cooperstone Jun 15, 2022 to now21
- Board memberEdward T. Mathers Jun 15, 2022 to now22
- Board memberSusan D. Berland Jun 15, 2022 to Jun 21, 202323
- Board memberTimothy K. Lu Jun 15, 2022 to now9
- Board memberDavid R. Epstein May 25, 2021 to Jul 15, 202224
- Board memberDipchand Nishar May 25, 2021 to May 25, 202125
- Board memberJay T. Flatley May 25, 2021 to May 25, 202126
- Board memberOmid Cameron Farokhzad May 25, 2021 to Jul 12, 202427
Former names
Timeline
- Jun 15, 2022New chief executive Timothy K. Lu becomes CEO9
Filings
333 filings to the SEC since October 2021: 7 annual reports, 17 quarterly reports, 76 major events, 77 insider forms, 36 large holders, 2 private raises, 118 other. The latest 20:
- Oct 15, 20268-K EDGAR
- Oct 13, 2026DEFA14A EDGAR
- Oct 13, 20268-K EDGAR
- Sep 24, 2026EFFECT EDGAR
- Sep 24, 20268-K EDGAR
- Sep 24, 2026424B3 EDGAR
- Sep 24, 2026DEFM14A EDGAR
- Sep 24, 2026PRER14A EDGAR
- Sep 22, 2026S-3/A EDGAR
- Sep 11, 2026SCHEDULE 13D/A EDGAR
- Sep 10, 2026S-3/A EDGAR
- Sep 4, 2026DEFA14A EDGAR
- Sep 4, 20268-K EDGAR
- Sep 4, 2026PRER14A EDGAR
- Sep 2, 2026DEFA14A EDGAR
- Sep 2, 20268-K EDGAR
- Aug 20, 2026DEFA14A EDGAR
- Aug 20, 20268-K EDGAR
- Aug 14, 202610-Q EDGAR
- Jul 21, 2026ARS EDGAR
The 333 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 36 such filings since October 2021, the latest 10:
- Sep 11, 2026SCHEDULE 13D/A
- Jul 16, 2026SCHEDULE 13D/A
- May 4, 2026SCHEDULE 13D/A
- Apr 16, 2026SCHEDULE 13D/A
- Mar 31, 2026SCHEDULE 13D/A
- Jan 20, 2026SCHEDULE 13D/A
- Sep 2, 2025SCHEDULE 13D/A
- May 15, 2025SCHEDULE 13G/A
- May 15, 2025SCHEDULE 13G/A
- May 15, 2025SCHEDULE 13G/A
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Money raised
Private offerings the company reported to the SEC on Form D.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Nantahala Capital Management, LLC | 888,000 | $976.8K | 0.0% | New |
| Vanguard Capital Management LLC | 537,504 | $591.3K | 0.0% | New |
| Geode Capital Management, LLC | 187,065 | $205.8K | 0.0% | New |
| Citadel Advisors LLC | 107,100 | $117.8K | 0.0% | New |
| Vanguard Fiduciary Trust Co | 91,193 | $100.3K | 0.0% | New |
| Jane Street Group, LLC | 52,530 | $57.8K | 0.0% | New |
| Menlo Ventures Management, L.P. | 35,737 | $39.3K | 0.0% | New |
| Northern Trust Corp | 32,154 | $35.4K | 0.0% | New |
| XTX Topco Ltd | 23,610 | $26.0K | 0.0% | New |
| UBS Group AG | 14,432 | $15.9K | 0.0% | New |
| Tower Research Capital LLC (TRC) | 7,344 | $8.1K | 0.0% | New |
| BlackRock, Inc. | 4,004 | $4.4K | 0.0% | New |
| Royal Bank Of Canada | 4,015 | $4.0K | 0.0% | New |
| Barclays PLC | 768 | $845 | 0.0% | New |
| SBI Securities Co., Ltd. | 334 | $367 | 0.0% | New |
| Morgan Stanley | 169 | $186 | 0.0% | New |
| Virtu Financial LLC | 22,795 | $25 | 0.0% | New |
| Caitong International Asset Management Co., Ltd | 1 | $1 | 0.0% | New |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11SEC EDGARYvonne Li, Chief financial officer
- 12
- 13
- 14
- 15
- 16
- 17
- 18SEC EDGARFeng Hsiung, Board member
- 19SEC EDGARBryan Daniel Baum, Board member
- 20SEC EDGARFran Schulz, Board member
- 21SEC EDGARBrenda Cooperstone, Board member
- 22SEC EDGAREdward T. Mathers, Board member
- 23SEC EDGARSusan D. Berland, Board member
- 24SEC EDGARDavid R. Epstein, Board member
- 25SEC EDGARDipchand Nishar, Board member
- 26SEC EDGARJay T. Flatley, Board member
- 27SEC EDGAROmid Cameron Farokhzad, Board member